Joint wear is common in active adults, causing pain and limiting everyday activities. Many people ask whether the ChondroFiller injection is complicated. The short answer is that it is a simple, non-surgical outpatient injection. This article explains what it involves, with realistic expectations throughout.

What Is ChondroFiller?

ChondroFiller is a CE-marked Class III medical device: an acellular type I collagen hydrogel scaffold manufactured by Meidrix Biomedicals in Germany and imported into the UK under prescription. It contains no donor cells. When injected into a prepared joint, it gels in place within a few minutes and acts as a structural matrix that recruits the patient's own progenitor cells from the surrounding tissue and subchondral bone, supporting the biological environment for cartilage repair. It is best understood as a joint-preserving, biologically supportive scaffold — not a cure and not a reversal of arthritis.

What Makes ChondroFiller Different from Liquid Cartilage Surgery?

It is worth clarifying an important distinction. The ChondroFiller injection is a non-surgical, ultrasound-guided outpatient procedure suited to accessible lesions where the material can be delivered without an incision. Liquid Cartilage is a separate, surgical pathway — Professor Paul Y. F. Lee's keyhole (arthroscopic) protocol that delivers the ChondroFiller scaffold alongside biological adjuncts and, where indicated, the patient's own mesenchymal stem cells, in a theatre setting with anaesthesia and structured rehabilitation. The two are not the same thing. This article concerns the injection pathway only.

Is the Injection Difficult?

Preparation is straightforward. Before treatment, the clinical team reviews imaging such as MRI and uses ultrasound to assess the joint and plan the injection site accurately. During the appointment, the clinician injects the warmed collagen scaffold into the joint through a fine needle under real-time ultrasound guidance. There is no incision and no removal of tissue. The gel sets within minutes inside the joint.

Comfort and Recovery

Patient comfort is a clinical priority. The injection is usually performed with a local anaesthetic to numb the area. Because it is non-surgical, recovery is straightforward — most people return to normal daily activities promptly and ease back into higher-impact activity as guided, with physiotherapy support where appropriate. There is no requirement for the protected weight-bearing or extended rehabilitation that follows surgery.

Safety

Like any injection, minor risks exist — for example, the gel not settling optimally, or temporary local swelling — but these are uncommon. Published data from the ChondroFiller device's clinical evaluation reports a very low overall complaint rate and no serious incidents across a large number of units used since 2013. Careful assessment of patient suitability, precise ultrasound-guided technique, and structured follow-up all contribute to minimising risk. Benefits vary between individuals and cannot be guaranteed.

In Summary

The ChondroFiller injection is a simple, non-surgical, outpatient procedure that may help support a worn joint for suitable patients. It is not a cure. For patients whose cartilage damage is more extensive or whose joint requires a surgical approach, the Liquid Cartilage keyhole procedure may be the more appropriate route — a distinction that a specialist assessment will clarify. The London Cartilage Clinic offers assessment to advise on whether the ChondroFiller injection, the Liquid Cartilage surgical protocol, or another option is most suited to your situation.

References

Corain M, Zanotti F, Giardini M, Gasperotti L, Invernizzi E, Biasi V, Lavagnolo U. The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage. 2023.